Podiatrist let unlicensed salesman perform surgery, then billed Medicare; Novo Nordisk partners with OpenAI to accelerate drug development; a better predictor of hypertension risk – Morning Medical Update
Article excerpt
California podiatrist let unlicensed salesman perform surgery, then billed Medicare Both men were sentenced to 63 months in prison for a $3.2 million health care fraud consipiracy. A California podiatrist and a pharmaceutical sales representative have each been sentenced to more than five years in prison for allowing the unlicensed salesman to perform surgical procedures - including using a scalpel to debride wounds on patients with recent foot amputations - while billing Medicare, Medicaid and Medi-Cal as if licensed physicians had done the work. Felipe Ruiz, D.P.M., 52, who owned West Coast Podiatry (WCP) in California's Central Valley, purchased skin grafts from Jose Aguirre, 53, and permitted him to apply them and perform other procedures on patients unsupervised between 2021 and 2024. Some patients believed Aguirre was a physician, calling him "Dr. Gabe." In one instance, WCP submitted $150,000 in Medicare claims for procedures performed while the physician of record was out of the country on vacation. Staff and third-party auditors raised concerns that were repeatedly ignored. In addition to their prison terms, Ruiz faces a $12.1 million forfeiture judgment and Aguirre a $2.6 million judgment, with nine properties also ordered forfeited. Novo Nordisk partners with OpenAI to accelerate drug development The deal covers research, manufacturing and commercial operations...
Keep reading with a free account
The rest of this article, and every signal for Novo Nordisk, is in your free account.
Extracted from this sentence
Novo Nordisk, the Danish drugmaker behind Ozempic and Wegovy, has announced a partnership with OpenAI, the artificial intelligence (AI) company behind ChatGPT, to deploy AI across its business, from drug discovery and manufacturing to supply chain and commercial operations, as they work to close the gap with Eli Lilly in the obesity drug market.
